Puma Biotechnology Net Asset
| PBYI Stock | USD 6.43 0.11 1.74% |
As of the 29th of January, Puma Biotechnology holds the Risk Adjusted Performance of 0.0839, semi deviation of 4.24, and Coefficient Of Variation of 962.28. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Puma Biotechnology, as well as the relationship between them.
Puma Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Puma Biotechnology's valuation are provided below:Puma Biotechnology does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Stock market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Puma Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Puma Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Puma Biotechnology.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Puma Biotechnology on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Puma Biotechnology or generate 0.0% return on investment in Puma Biotechnology over 90 days. Puma Biotechnology is related to or competes with Eledon Pharmaceuticals, Abeona Therapeutics, Voyager Therapeutics, Atea Pharmaceuticals, Arcturus Therapeutics, Allogene Therapeutics, and Humacyte. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to e... More
Puma Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Puma Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Puma Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.69 | |||
| Information Ratio | 0.091 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (3.81) | |||
| Potential Upside | 4.39 |
Puma Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Puma Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Puma Biotechnology's standard deviation. In reality, there are many statistical measures that can use Puma Biotechnology historical prices to predict the future Puma Biotechnology's volatility.| Risk Adjusted Performance | 0.0839 | |||
| Jensen Alpha | 0.4643 | |||
| Total Risk Alpha | 0.1472 | |||
| Sortino Ratio | 0.0917 | |||
| Treynor Ratio | 1.45 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Puma Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Puma Biotechnology January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0839 | |||
| Market Risk Adjusted Performance | 1.46 | |||
| Mean Deviation | 2.68 | |||
| Semi Deviation | 4.24 | |||
| Downside Deviation | 4.69 | |||
| Coefficient Of Variation | 962.28 | |||
| Standard Deviation | 4.73 | |||
| Variance | 22.36 | |||
| Information Ratio | 0.091 | |||
| Jensen Alpha | 0.4643 | |||
| Total Risk Alpha | 0.1472 | |||
| Sortino Ratio | 0.0917 | |||
| Treynor Ratio | 1.45 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (3.81) | |||
| Potential Upside | 4.39 | |||
| Downside Variance | 22.0 | |||
| Semi Variance | 17.95 | |||
| Expected Short fall | (3.02) | |||
| Skewness | 0.14 | |||
| Kurtosis | 13.49 |
Puma Biotechnology Backtested Returns
Puma Biotechnology appears to be moderately volatile, given 3 months investment horizon. Puma Biotechnology maintains Sharpe Ratio (i.e., Efficiency) of 0.1, which implies the firm had a 0.1 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Puma Biotechnology, which you can use to evaluate the volatility of the company. Please evaluate Puma Biotechnology's Coefficient Of Variation of 962.28, risk adjusted performance of 0.0839, and Semi Deviation of 4.24 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Puma Biotechnology holds a performance score of 8. The company holds a Beta of 0.33, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Puma Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Puma Biotechnology is expected to be smaller as well. Please check Puma Biotechnology's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Puma Biotechnology's historical price patterns will revert.
Auto-correlation | 0.44 |
Average predictability
Puma Biotechnology has average predictability. Overlapping area represents the amount of predictability between Puma Biotechnology time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Puma Biotechnology price movement. The serial correlation of 0.44 indicates that just about 44.0% of current Puma Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | 0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Puma Biotechnology has a Net Asset of 213.33 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Puma Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics of similar companies.Puma Biotechnology is currently under evaluation in net asset category among its peers.
Puma Fundamentals
| Return On Equity | 0.4 | |||
| Return On Asset | 0.099 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 277.73 M | |||
| Shares Outstanding | 50.39 M | |||
| Shares Owned By Insiders | 15.38 % | |||
| Shares Owned By Institutions | 72.02 % | |||
| Number Of Shares Shorted | 3.59 M | |||
| Price To Earning | 18.52 X | |||
| Price To Book | 2.87 X | |||
| Price To Sales | 1.50 X | |||
| Revenue | 230.47 M | |||
| Gross Profit | 163.04 M | |||
| EBITDA | 48.08 M | |||
| Net Income | 30.28 M | |||
| Cash And Equivalents | 77.96 M | |||
| Cash Per Share | 1.71 X | |||
| Total Debt | 74.08 M | |||
| Debt To Equity | 5.19 % | |||
| Current Ratio | 2.04 X | |||
| Book Value Per Share | 2.29 X | |||
| Cash Flow From Operations | 38.92 M | |||
| Short Ratio | 9.67 X | |||
| Earnings Per Share | 0.74 X | |||
| Price To Earnings To Growth | 0.03 X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 172 | |||
| Beta | 1.18 | |||
| Market Capitalization | 318.47 M | |||
| Total Asset | 213.33 M | |||
| Retained Earnings | (1.31 B) | |||
| Working Capital | 51.55 M | |||
| Current Asset | 223.55 M | |||
| Current Liabilities | 32.44 M | |||
| Net Asset | 213.33 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is there potential for Stock market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.